Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
about
Focus on adoptive T cell transfer trials in melanomaChimeric antigen receptor-modified T cells in chronic lymphoid leukemiaA transposon and transposase system for human applicationT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaGenetic engineering of T cells for adoptive immunotherapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesNovel immunotherapies in lymphoid malignanciesAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsCARs in chronic lymphocytic leukemia -- ready to driveProgress and prospects for engineered T cell therapiesGenetically modified T cells for the treatment of malignant diseaseRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondNovel immunotherapies for hematologic malignanciesAdoptive T-cell therapy for LeukemiaClinical application of adoptive T cell therapy in solid tumorsAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsCD19 as an attractive target for antibody-based therapyAntigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsGenetically modified T cells in cancer therapy: opportunities and challengesChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaCAR therapy: the CD19 paradigmAre BiTEs the "missing link" in cancer therapy?Designing chimeric antigen receptors to effectively and safely target tumorsCombining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaHow (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferChimeric antigen receptor T cells for sustained remissions in leukemiaChimeric antigen receptor-modified T cells for acute lymphoid leukemiaCase report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasSleeping beauty system to redirect T-cell specificity for human applications.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.Engineered T cells for cancer treatmentLentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
P2860
Q21328679-A07548CF-5E6F-4315-8BE6-A094074855D2Q24594920-18150D07-E585-4908-A664-B6E79E918880Q24630047-F7FE60D7-4B25-4C83-AE16-50D93D37E21DQ24632975-B6230E8A-E0E9-477D-A063-099B0DA4E406Q24642718-E9E9EC66-7BD6-44C1-87DB-00A34D2D4751Q26773309-064E8B4A-4401-4E26-B7C4-F15C70BA8C28Q26775720-3A9A1F65-3165-4046-9AC1-A36C40B3149BQ26777394-6B1784A9-143E-4AC6-B414-C15410EA197AQ26795540-3123B6CE-6B3D-4A4E-AAFD-09CA2384E1B5Q26830526-0D41F76A-E4C7-4867-B5A7-BA12716F991BQ26852923-0098CF20-2476-446E-8A3F-F2FFFAADB431Q26860657-5F786FDD-A50E-41AD-BB1B-B7574ABCD8CBQ26861563-4A0DEF91-DFFE-4E0D-BDFE-A058D1614D1CQ27004436-89542D6F-75CF-4B87-A244-095600A63908Q27006934-44894E1A-5E87-4124-AABC-9952AE3CBBF5Q27011283-CABACD3D-E91F-4A01-83A3-043A1968DD79Q27011298-5C6041C6-3E46-4842-AAE2-21F18AAA27A3Q27011836-F3C76B93-0E65-45C1-A229-9CE44B2DF80DQ27026484-04D2B4A5-137E-47D2-ABA8-909DA4D15F9FQ27026627-02EFFAE1-3B2C-4EAF-842A-BC996CF7F288Q27312288-B9A6A41D-6118-4601-BB23-F01C42E73AB7Q28081600-00E59668-0F69-4EB1-9249-2DA1B759E16FQ28081642-D48FB46B-625D-4D7A-8C10-12F2CA52C18AQ28083907-690B37B2-C5CF-4450-BA65-8E13E5D3ECEEQ28088526-3359B7E3-4E0F-4B3A-BD13-664F74275CF0Q28537688-621C26B8-B132-4525-B58F-1077E1D55CB0Q28727481-E561F991-4FEA-4E07-AD9A-759B5D941F7CQ29617588-ECD28E5C-CA19-4727-9DC9-CFC5C76CD82BQ29620130-2FC4813F-DA07-454A-86AC-D48F35700F80Q29620608-51040B6F-080C-427D-BE36-9A4BB1B3B99DQ29620717-331BC23F-82EF-43FA-AACE-B69FD360F34EQ29622949-07939B2A-5B9A-4F99-BCB1-ACCB6AF83ADAQ30535187-D99A68CB-5F21-49CF-B812-5880058F16D9Q30584839-FA29628D-3CAB-40F0-ACFF-90A45AD8EECCQ30667174-CC46FF8C-F636-4C5E-8AAF-43F07724328DQ30764873-32EFE3A7-091C-4341-9A05-2AC84F866EB2Q33530527-D0367534-3354-44A6-AB38-4E851641E5D9Q33560416-E853B8D3-FD08-4133-9DB9-073670A6F918Q33578792-D27DE2ED-148D-429D-AB4B-7A7DEA609DFFQ33688441-4F8C8306-540C-445E-9A1F-DB2A9CE8FE44
P2860
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Adoptive immunotherapy for ind ...... tologous CD20-specific T cells
@en
type
label
Adoptive immunotherapy for ind ...... tologous CD20-specific T cells
@en
prefLabel
Adoptive immunotherapy for ind ...... tologous CD20-specific T cells
@en
P2093
P2860
P1433
P1476
Adoptive immunotherapy for ind ...... tologous CD20-specific T cells
@en
P2093
Andrew Raubitschek
Brent L Wood
Brian G Till
Catherine G Lindgren
Eric Y Chen
Harvey A Greisman
Jinjuan Wang
John M Pagel
Michael C Jensen
Philip D Greenberg
P2860
P304
P356
10.1182/BLOOD-2007-12-128843
P407
P577
2008-05-28T00:00:00Z